← Back to headlines
Castle Biosciences Projects $340M-$350M Revenue for 2026
Castle Biosciences has outlined its 2026 revenue target, projecting between $340 million and $350 million, supported by the launch of AdvanceAD-Tx.
27 Feb, 01:58 — 27 Feb, 01:58
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
NFA relaxes palay-buying rules to benefit farmers
just now
Venezuela suspends 19 oil, gas production-sharing contracts signed under Maduro, sources say
just now
Unexpected end to the race for TVN's owner. Netflix made a decision
4m ago
Cable One targets Q1 2026 mobile launch and $480M MBI acquisition while advancing multi-gig upgrades
8m ago